Karina Thorn

Karina Thorn is an accomplished professional with extensive experience in the field of nucleic acid research and therapy. Serving as Corporate Vice President at Novo Nordisk from September 2021 to March 2025, Karina held leadership positions in Nucleic Acid Research, Global Nucleic Acid Therapies, and RNA and Gene Therapies. Presently, Karina is a Board Member of the Danish RNA Society, contributing to advancements in RNA-related research. Prior to this, Karina served as a Scientist and Project Leader at Biogen Idec Hemophilia, focusing on protein chemistry and peptide research from November 2008 to May 2014. Academic qualifications include a postdoctoral position in Pharmaceutical Sciences from the University of Copenhagen and various leadership training programs at Korn Ferry and Deloitte.